Brief: AB Science Receives Health Canada Approval Letter To Commence Phase I/II Trial Of AB8939
22/09/2021 17:26
Sept 22 (Reuters) - AB Science SA ABS.PA :
* REG-AB SCIENCE RECEIVES HEALTH CANADA APPROVAL LETTER TO COMMENCE PHASE
I/II
TRIAL OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)
* AB SCIENCE SA - 'NO OBJECTION LETTER' (NOL) PROVIDES ACKNOWLEDGEMENT OF
AB8939'S DRUG CANDIDACY AND AUTHORITY TO PROCEED WITH A PHASE I/II STUDY
(AB18001) IN PATIENTS WITH REFRACTORY AND RELAPSED AML AND REFRACTORY
MYELODYSPLASTIC SYNDROME (MDS)
* AB SCIENCE SA - AB8939 WAS ENTIRELY DISCOVERED BY LABORATORIES OF AB
SCIENCE,
WHICH RETAINS FULL OWNERSHIP OF INTELLECTUAL RIGHTS,
Source text for Eikon: ID:nGNE3K8Kjv
Further company coverage: ABS.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease